{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:52:09Z","timestamp":1791280329999,"version":"4.1.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004252","name":"Qatar University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Triple-negative breast cancer (TNBC) represents one of its most aggressive subtypes, characterized by poor prognosis and resistance to conventional therapies. Given the urgent need for more effective treatment strategies, chalcone derivatives have attracted attention as versatile scaffolds with multitarget anticancer potential. In this study, we evaluated the anticancer efficacy of 14 novel pyridine-based chalcone analogs against TNBC cell lines (MDA-MB-231 and BT-20). Following initial screening,\n                    <jats:bold>OH17<\/jats:bold>\n                    and\n                    <jats:bold>OH25<\/jats:bold>\n                    showed promising activity and were selected for further evaluation alongside docetaxel (DTX), a standard chemotherapeutic control. Both OH17 and OH25 significantly reduced TNBC cell viability at low micromolar concentrations. Morphological analysis revealed apoptosis-like features, further supported by cell cycle analysis and Annexin V\/PI staining, which demonstrated sub-G1 accumulation and induction of apoptosis. Molecular pathway analysis showed that the compounds upregulated the pro-apoptotic protein BAX while downregulating ERK1\/2, with\n                    <jats:bold>OH17<\/jats:bold>\n                    showing additional EGFR modulation. These effects translated into significant inhibition of cell invasion and colony formation, underscoring their potential to suppress key hallmarks of TNBC aggressiveness. Collectively, our findings highlight\n                    <jats:bold>OH17<\/jats:bold>\n                    and\n                    <jats:bold>OH25<\/jats:bold>\n                    as promising chalcone analogs with potent and mechanistically distinct therapeutic activity against TNBC. These results support further preclinical evaluation of pyridine chalcones as next-generation candidates for TNBC therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-51789-0","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T15:03:01Z","timestamp":1780153381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel pyridine-based chalcone analogs and triple negative breast cancer: potential therapy &amp; molecular pathways"],"prefix":"10.1038","volume":"16","author":[{"given":"Arij Fouzat","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola J.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeel","family":"Kheraldine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumayyah","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysaloun","family":"Merhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jericha Miles","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamda","family":"Al-Thawadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feras","family":"Alali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala-Eddin","family":"Al-Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelbary","family":"Elhissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"4","key":"51789_CR1","first-page":"195","volume":"2","author":"J Luo","year":"2022","unstructured":"Luo, J. et al. Etiology of breast cancer: A perspective from epidemiologic studies. J. Natl. Cancer Cent. 2(4), 195\u20137 (2022).","journal-title":"J. Natl. Cancer Cent."},{"issue":"3","key":"51789_CR2","first-page":"287","volume":"5","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Global burden of female breast cancer: New estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN. J. Natl. Cancer Cent. 5(3), 287\u201396 (2025).","journal-title":"J. Natl. Cancer Cent."},{"key":"51789_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174287","author":"S Lukasiewicz","year":"2021","unstructured":"Lukasiewicz, S. et al. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13174287 (2021).","journal-title":"Cancers (Basel)"},{"key":"51789_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103674","volume":"74","author":"MJ Cardoso","year":"2024","unstructured":"Cardoso, M. J., Poortmans, P., Senkus, E., Gentilini, O. D. & Houssami, N. Breast cancer highlights from 2023: Knowledge to guide practice and future research. Breast 74, 103674 (2024).","journal-title":"Breast"},{"key":"51789_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104351","volume":"197","author":"MM Khan","year":"2024","unstructured":"Khan, M. M., Yalamarty, S. S. K., Rajmalani, B. A., Filipczak, N. & Torchilin, V. P. Recent strategies to overcome breast cancer resistance. Crit. Rev. Oncol. Hematol. 197, 104351 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"51789_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.clbc.2024.03.001","volume":"24","author":"E Michaels","year":"2024","unstructured":"Michaels, E., Chen, N. & Nanda, R. The role of immunotherapy in triple-negative breast cancer (TNBC). Clin. Breast Cancer 24(4), 263\u2013270 (2024).","journal-title":"Clin. Breast Cancer"},{"issue":"21","key":"51789_CR7","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid, P. et al. Overall survival with Pembrolizumab in early-stage triple-negative breast cancer. N. Engl. J. Med. 391(21), 1981\u201391 (2024).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"51789_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami, P. & Carey, L. A. Triple negative breast cancer: Pitfalls and progress. npj Breast Cancer 8(1), 95 (2022).","journal-title":"npj Breast Cancer"},{"issue":"1","key":"51789_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2023.151548","volume":"40","author":"G Patel","year":"2024","unstructured":"Patel, G., Prince, A. & Harries, M. Advanced triple-negative breast cancer. Semin. Oncol. Nurs. 40(1), 151548 (2024).","journal-title":"Semin. Oncol. Nurs."},{"issue":"1","key":"51789_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin, L., Duan, J. J., Bian, X. W. & Yu, S. C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22 (1), 61 (2020).","journal-title":"Breast Cancer Res."},{"issue":"1","key":"51789_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J. Hematol. Oncol. 15(1), 121 (2022).","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"51789_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000046962","volume":"105","author":"Y Jiang","year":"2026","unstructured":"Jiang, Y. et al. Comparing efficacy of neoadjuvant therapy of triple-negative breast cancer: A Bayesian network meta-regression analysis. Medicine (Baltimore) 105(2), e46962 (2026).","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"51789_CR13","doi-asserted-by":"publisher","first-page":"105923","DOI":"10.1016\/j.esmoop.2025.105923","volume":"10","author":"M de Graaf","year":"2025","unstructured":"de Graaf, M. et al. Pathological complete response and survival after neoadjuvant chemotherapy in patients with stage I TNBC: A registry-based study. ESMO. Open. 10(12), 105923 (2025).","journal-title":"ESMO. Open."},{"issue":"1","key":"51789_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03435-w","volume":"16","author":"Y Du","year":"2025","unstructured":"Du, Y. & Huang, L. Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis. Discov. Oncol. 16(1), 1567 (2025).","journal-title":"Discov. Oncol."},{"issue":"40","key":"51789_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000044740","volume":"104","author":"J Wu","year":"2025","unstructured":"Wu, J., Yan, X., Fang, J., Peng, L. & Zhao, X. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: An updated systematic review and meta-analysis. Medicine (Baltimore) 104(40), e44740 (2025).","journal-title":"Medicine (Baltimore)"},{"key":"51789_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/cancers17243961","volume":"17","author":"I Taglialatela","year":"2025","unstructured":"Taglialatela, I. et al. Updating the Role of Carboplatin Added to Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis. Cancers (Basel). 17, 24 (2025).","journal-title":"Cancers (Basel)"},{"key":"51789_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237177","author":"M Rudrapal","year":"2021","unstructured":"Rudrapal, M. et al. Chalcone scaffolds, bioprecursors of flavonoids: Chemistry, bioactivities, and pharmacokinetics. Molecules https:\/\/doi.org\/10.3390\/molecules26237177 (2021).","journal-title":"Molecules"},{"issue":"14","key":"51789_CR18","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2174\/1381612826666200206095400","volume":"26","author":"A Mahmoud","year":"2020","unstructured":"Mahmoud, A., Elkhalifa, D., Alali, F., Al Moustafa, A. E. & Khalil, A. Novel polymethoxylated chalcones as potential compounds against KRAS-mutant colorectal cancers. Curr. Pharm. Des. 26(14), 1622\u201333 (2020).","journal-title":"Curr. Pharm. Des."},{"key":"51789_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7651047","volume":"2016","author":"M Das","year":"2016","unstructured":"Das, M. & Manna, K. Chalcone scaffold in anticancer armamentarium: A molecular insight. J. Toxicol. 2016, 7651047 (2016).","journal-title":"J. Toxicol."},{"issue":"3","key":"51789_CR20","first-page":"422","volume":"13","author":"V Sharma","year":"2013","unstructured":"Sharma, V., Kumar, V. & Kumar, P. Heterocyclic chalcone analogues as potential anticancer agents. Anti-Cancer Agents Med. Chem. 13(3), 422\u2013432 (2013).","journal-title":"Anti-Cancer Agents Med. Chem."},{"issue":"37","key":"51789_CR21","doi-asserted-by":"publisher","first-page":"7658","DOI":"10.2174\/0929867328666210511014949","volume":"28","author":"T Martins","year":"2021","unstructured":"Martins, T., Fonseca, B. M. & Rebelo, I. Antioxidant effects of chalcones during the inflammatory response: An overall review. Curr. Med. Chem. 28(37), 7658\u2013713 (2021).","journal-title":"Curr. Med. Chem."},{"key":"51789_CR22","doi-asserted-by":"publisher","first-page":"106129","DOI":"10.1016\/j.micpath.2023.106129","volume":"180","author":"ATL Dos Santos","year":"2023","unstructured":"Dos Santos, A. T. L. et al. Synthesis of chalcones and their antimicrobial and drug potentiating activities. Microb. Pathog. 180, 106129 (2023).","journal-title":"Microb. Pathog."},{"issue":"4","key":"51789_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/1061186X.2020.1853759","volume":"29","author":"D Elkhalifa","year":"2021","unstructured":"Elkhalifa, D., Al-Hashimi, I., Al Moustafa, A. E. & Khalil, A. A comprehensive review on the antiviral activities of chalcones. J. Drug Target. 29(4), 403\u201319 (2021).","journal-title":"J. Drug Target."},{"issue":"28","key":"51789_CR24","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.2174\/1568026617666170914160446","volume":"17","author":"DK Mahapatra","year":"2017","unstructured":"Mahapatra, D. K., Bharti, S. K. & Asati, V. Chalcone derivatives: Anti-inflammatory potential and molecular targets perspectives. Curr. Top. Med. Chem. 17(28), 3146\u201369 (2017).","journal-title":"Curr. Top. Med. Chem."},{"key":"51789_CR25","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.2147\/DDDT.S316185","volume":"15","author":"S Welday Kahssay","year":"2021","unstructured":"Welday Kahssay, S., Hailu, G. S. & Taye Desta, K. Design, synthesis, characterization and in vivo antidiabetic activity evaluation of some chalcone derivatives. Drug Des. Devel. Ther. 15, 3119\u201329 (2021).","journal-title":"Drug Des. Devel. Ther."},{"key":"51789_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/biom11060894","author":"Y Ouyang","year":"2021","unstructured":"Ouyang, Y. et al. Chalcone derivatives: Role in anticancer therapy. Biomolecules https:\/\/doi.org\/10.3390\/biom11060894 (2021).","journal-title":"Biomolecules"},{"issue":"8","key":"51789_CR27","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1080\/1061186X.2018.1561889","volume":"27","author":"D Elkhalifa","year":"2019","unstructured":"Elkhalifa, D., Alali, F., Al Moustafa, A.-E. & Khalil, A. Targeting triple negative breast cancer heterogeneity with chalcones: A molecular insight. J. Drug Target. 27(8), 830\u20138 (2019).","journal-title":"J. Drug Target."},{"key":"51789_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.110297","volume":"369","author":"AA WalyEldeen","year":"2023","unstructured":"WalyEldeen, A. A., Sabet, S., El-Shorbagy, H. M., Abdelhamid, I. A. & Ibrahim, S. A. Chalcones: Promising therapeutic agents targeting key players and signaling pathways regulating the hallmarks of cancer. Chem. Biol. Interact. 369, 110297 (2023).","journal-title":"Chem. Biol. Interact."},{"key":"51789_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112730","author":"R Michalkova","year":"2021","unstructured":"Michalkova, R., Mirossay, L., Gazdova, M., Kello, M. & Mojzis, J. Molecular mechanisms of antiproliferative effects of natural chalcones. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13112730 (2021).","journal-title":"Cancers (Basel)"},{"key":"51789_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.biopha.2018.05.126","volume":"105","author":"N Dong","year":"2018","unstructured":"Dong, N. et al. Apoptosis-inducing effects and growth inhibitory of a novel chalcone, in human hepatic cancer cells and lung cancer cells. Biomed. Pharmacother. 105, 195\u2013203 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"51789_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.592654","volume":"11","author":"B Salehi","year":"2020","unstructured":"Salehi, B. et al. Pharmacological properties of chalcones: A review of preclinical including molecular mechanisms and clinical evidence. Front. Pharmacol. 11, 592654 (2020).","journal-title":"Front. Pharmacol."},{"key":"51789_CR32","doi-asserted-by":"publisher","first-page":"111954","DOI":"10.1016\/j.ejmech.2019.111954","volume":"187","author":"D Elkhalifa","year":"2020","unstructured":"Elkhalifa, D. et al. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer. Eur. J. Med. Chem. 187, 111954 (2020).","journal-title":"Eur. J. Med. Chem."},{"issue":"32","key":"51789_CR33","doi-asserted-by":"publisher","first-page":"27769","DOI":"10.1021\/acsomega.2c01779","volume":"7","author":"NAA Elkanzi","year":"2022","unstructured":"Elkanzi, N. A. A. et al. Synthesis of chalcones derivatives and their biological activities: A review. ACS Omega 7(32), 27769\u201386 (2022).","journal-title":"ACS Omega"},{"key":"51789_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cbi.2018.07.005","volume":"292","author":"P Takac","year":"2018","unstructured":"Takac, P. et al. New chalcone derivative exhibits antiproliferative potential by inducing G2\/M cell cycle arrest, mitochondrial-mediated apoptosis and modulation of MAPK signalling pathway. Chem. Biol. Interact. 292, 37\u201349 (2018).","journal-title":"Chem. Biol. Interact."},{"issue":"1","key":"51789_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16199-3","volume":"7","author":"TR Mielcke","year":"2017","unstructured":"Mielcke, T. R. et al. Mechanisms underlying the antiproliferative effects of a series of quinoxaline-derived chalcones. Sci. Rep. 7(1), 15850 (2017).","journal-title":"Sci. Rep."},{"key":"51789_CR36","unstructured":"Ashraf Khalil, A-E-A-M. & Hussein, O. Arij Fouzat Hassan & Feras Alali, inventorPyridine based chalcone analogs as therapeutic agnets and use thereof Qatar (2025)."},{"issue":"2","key":"51789_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cpt.2023.06.002","volume":"2","author":"M Shi","year":"2024","unstructured":"Shi, M. et al. Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis. Cancer Pathog Ther. 2 (2), 81\u201390 (2024).","journal-title":"Cancer Pathog Ther."},{"key":"51789_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911595","author":"T Constantinescu","year":"2022","unstructured":"Constantinescu, T. & Mihis, A. G. Two important anticancer mechanisms of natural and synthetic chalcones. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms231911595 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"51789_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28104009","author":"FF Leite","year":"2023","unstructured":"Leite, F. F. et al. Anticancer activity of chalcones and its derivatives: Review and in silico studies. Molecules https:\/\/doi.org\/10.3390\/molecules28104009 (2023).","journal-title":"Molecules"},{"issue":"13","key":"51789_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33814","volume":"10","author":"FH Al-Ostoot","year":"2024","unstructured":"Al-Ostoot, F. H. et al. Structural and theoretical exploration of a multi-methoxy chalcone: Synthesis, quantum theory, electrostatics, molecular packing, DFT analysis, and in-silico anti-cancer evaluation. Heliyon 10(13), e33814 (2024).","journal-title":"Heliyon"},{"key":"51789_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13765-022-00686-x","author":"S Ahn","year":"2022","unstructured":"Ahn, S. et al. Design, synthesis, and biological evaluation of chalcones for anticancer properties targeting glycogen synthase kinase 3 beta. Appl. Biol. Chem. https:\/\/doi.org\/10.1186\/s13765-022-00686-x (2022).","journal-title":"Appl. Biol. Chem."},{"key":"51789_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30143009","author":"M Novas","year":"2025","unstructured":"Novas, M. & Matos, M. J. The role of trifluoromethyl and trifluoromethoxy groups in medicinal chemistry: Implications for drug design. Molecules https:\/\/doi.org\/10.3390\/molecules30143009 (2025).","journal-title":"Molecules"},{"key":"51789_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ph13110375","author":"SB Lagu","year":"2020","unstructured":"Lagu, S. B., Yejella, R. P., Bhandare, R. R. & Shaik, A. B. Design, synthesis, and antibacterial and antifungal activities of novel trifluoromethyl and trifluoromethoxy substituted chalcone derivatives. Pharmaceuticals (Basel) https:\/\/doi.org\/10.3390\/ph13110375 (2020).","journal-title":"Pharmaceuticals (Basel)"},{"key":"51789_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26092812","author":"Y Saito","year":"2021","unstructured":"Saito, Y. et al. Alpha-trifluoromethyl chalcones as potent anticancer agents for androgen receptor-independent prostate cancer. Molecules https:\/\/doi.org\/10.3390\/molecules26092812 (2021).","journal-title":"Molecules"},{"key":"51789_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202301189","author":"MF Polat","year":"2023","unstructured":"Polat, M. F. et al. New fluoro- and trifluoromethyl\u2010substituted trimethoxychalcones as anticancer agents: Synthesis, bio\u2010evaluation, and computational studies. ChemistrySelect https:\/\/doi.org\/10.1002\/slct.202301189 (2023).","journal-title":"ChemistrySelect"},{"issue":"6","key":"51789_CR46","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.21873\/anticanres.16411","volume":"43","author":"T Shimada","year":"2023","unstructured":"Shimada, T. et al. Novel alpha-Trifluoromethyl Chalcone Exerts Antitumor Effects Against Prostate Cancer Cells. Anticancer Res. 43 (6), 2433\u20132444 (2023).","journal-title":"Anticancer Res."},{"issue":"12","key":"51789_CR47","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.1021\/acs.jcim.0c00898","volume":"60","author":"A Abula","year":"2020","unstructured":"Abula, A. et al. Substitution Effect of the Trifluoromethyl Group on the Bioactivity in Medicinal Chemistry: Statistical Analysis and Energy Calculations. J. Chem. Inf. Model. 60 (12), 6242\u20136250 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"51789_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2024.101633","volume":"9","author":"SS Sankhe","year":"2024","unstructured":"Sankhe, S. S. & Mukadam, V. M. Pyridine-based chalcones as promising anticancer agents: Design, synthesis and in silico studies. Results Chem. 9, 101633 (2024).","journal-title":"Results Chem."},{"key":"51789_CR49","volume-title":"Heterocyclic Chemistry - New Perspectives","author":"S Chaudhary","year":"2024","unstructured":"Chaudhary, S., Sahu, N. K. & Mahajan, A. T. Pharmaceutically Privileged Bioactive Pyridine Derivatives as Anticancer Agents: Synthetic Developments and Biological Applications. In Heterocyclic Chemistry - New Perspectives (ed. Ali, R.) (IntechOpen, 2024)."},{"issue":"3","key":"51789_CR50","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s43440-025-00721-w","volume":"77","author":"SH Lee","year":"2025","unstructured":"Lee, S. H. et al. Chalcone-9: A novel inhibitor of the JAK-STAT pathway with potent anti-cancer effects in triple-negative breast cancer cells. Pharmacol. Rep. 77(3), 761\u201374 (2025).","journal-title":"Pharmacol. Rep."},{"key":"51789_CR51","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.bmcl.2024.129795","volume":"107","author":"P Kumar","year":"2024","unstructured":"Kumar, P. et al. Design, synthesis, and biological evaluation of chalcone acetamide derivatives against triple negative breast cancer. Bioorganic & Medicinal Chem. Lett. 107, 1464\u20133405 (2024) ((Electronic)).).","journal-title":"Bioorganic & Medicinal Chem. Lett."},{"key":"51789_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23082018","author":"TT Komoto","year":"2018","unstructured":"Komoto, T. T. et al. Chalcones repressed the AURKA and MDR proteins involved in metastasis and multiple drug resistance in breast cancer cell lines. Molecules https:\/\/doi.org\/10.3390\/molecules23082018 (2018).","journal-title":"Molecules"},{"issue":"2","key":"51789_CR53","doi-asserted-by":"publisher","first-page":"683","DOI":"10.31557\/APJCP.2023.24.2.683","volume":"24","author":"N Padauleng","year":"2023","unstructured":"Padauleng, N., Mustofa, M., Wahyuningsih, T. D. & Purnomosari, D. Chalcone-3 inhibits the proliferation of human breast cancer MDA-MB-231 cell line. Asian Pac. J. Cancer Prev. 24(2), 683\u201391 (2023).","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"51789_CR54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13046-016-0315-1","volume":"35","author":"M Wang","year":"2016","unstructured":"Wang, M. et al. N-Hydroxyphthalimide exhibits antitumor activity by suppressing mTOR signaling pathway in BT-20 and LoVo cells. J. Exp. Clin. Cancer Res. 3541. (2016).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"51789_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11051484","author":"KN Ncube","year":"2023","unstructured":"Ncube, K. N. et al. Comparative evaluation of the cytotoxicity of doxorubicin in BT-20 triple-negative breast carcinoma monolayer and spheroid cultures. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines11051484 (2023).","journal-title":"Biomedicines"},{"issue":"22","key":"51789_CR56","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.3390\/cells13221838","volume":"13","author":"M Mustafa","year":"2024","unstructured":"Mustafa, M. et al. Apoptosis: A Comprehensive Overview of Signaling Pathways, Morphological Changes, and Physiological Significance and Therapeutic Implications. Cells 13(22), 1838 (2024).","journal-title":"Cells"},{"issue":"11","key":"51789_CR57","doi-asserted-by":"publisher","first-page":"e1007493","DOI":"10.1371\/journal.pcbi.1007493","volume":"15","author":"JV Anttila","year":"2019","unstructured":"Anttila, J. V. et al. Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression. PLoS Comput. Biol. 15 (11), e1007493 (2019).","journal-title":"PLoS Comput. Biol."},{"key":"51789_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101959","author":"M Imran","year":"2020","unstructured":"Imran, M., Saleem, S., Chaudhuri, A., Ali, J. & Baboota, S. Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer. J. Drug Deliv. Sci. Technol. https:\/\/doi.org\/10.1016\/j.jddst.2020.101959 (2020).","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"1","key":"51789_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-022-10466-x","volume":"23","author":"BY Peng","year":"2023","unstructured":"Peng, B. Y. et al. AGA induces sub-G1 cell cycle arrest and apoptosis in human colon cancer cells through p53-independent\/p53-dependent pathway. BMC. Cancer 23(1), 1 (2023).","journal-title":"BMC. Cancer"},{"key":"51789_CR60","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0076-6879(08)01606-6","volume":"446","author":"D Plesca","year":"2008","unstructured":"Plesca, D., Mazumder, S. & Almasan, A. DNA damage response and apoptosis. Methods Enzymol. 446, 107\u201322 (2008).","journal-title":"Methods Enzymol."},{"key":"51789_CR61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12935-016-0315-4","volume":"16","author":"H Murad","year":"2016","unstructured":"Murad, H. et al. Induction of G1-phase cell cycle arrest and apoptosis pathway in MDA-MB-231 human breast cancer cells by sulfated polysaccharide extracted from Laurencia papillosa. Cancer Cell. Int. 16, 39 (2016).","journal-title":"Cancer Cell. Int."},{"issue":"11","key":"51789_CR62","doi-asserted-by":"publisher","first-page":"10421","DOI":"10.1007\/s11033-022-07757-8","volume":"49","author":"SZ Shahrokhi","year":"2022","unstructured":"Shahrokhi, S. Z., Tehrani, F. S. K. & Salami, S. Molecular mechanisms of bilirubin induced G1 cell cycle arrest and apoptosis in human breast cancer cell lines: Involvement of the intrinsic pathway. Mol. Biol. Rep. 49(11), 10421\u201310429 (2022).","journal-title":"Mol. Biol. Rep."},{"key":"51789_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmcr.2025.100250","author":"GR Stringhetta","year":"2025","unstructured":"Stringhetta, G. R. et al. Design, synthesis and evaluation of quinazoline-chalcone hybrids as inducers of cell-cycle arrest and apoptosis in breast cancer via DNA damage and CDK2\/ATR inhibition. Eur. J. Med. Chem. Rep. https:\/\/doi.org\/10.1016\/j.ejmcr.2025.100250 (2025).","journal-title":"Eur. J. Med. Chem. Rep."},{"issue":"1","key":"51789_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4238\/gmr.15017321","volume":"15","author":"TD Han","year":"2016","unstructured":"Han, T. D., Shang, D. H. & Tian, Y. Docetaxel enhances apoptosis and G2\/M cell cycle arrest by suppressing mitogen-activated protein kinase signaling in human renal clear cell carcinoma. Genet. Mol. Res. 15(1), 1\u201310 (2016).","journal-title":"Genet. Mol. Res."},{"issue":"7","key":"51789_CR65","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1134\/S1070363224070235","volume":"94","author":"J Sharma","year":"2024","unstructured":"Sharma, J. & Kaushal, R. Nitrogen containing heterocyclic chalcone hybrids and their biological potential (A review). Russ. J. Gen. Chem. 94(7), 1794\u20131814 (2024).","journal-title":"Russ. J. Gen. Chem."},{"key":"51789_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154087","volume":"101","author":"XX Jin","year":"2022","unstructured":"Jin, X. X. et al. A chalcone-syringaldehyde hybrid inhibits triple-negative breast cancer cell proliferation and migration by inhibiting CKAP2-mediated FAK and STAT3 phosphorylation. Phytomedicine 101, 154087 (2022).","journal-title":"Phytomedicine"},{"issue":"3","key":"51789_CR67","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/prm2.12107","volume":"12","author":"Y Gao","year":"2023","unstructured":"Gao, Y. et al. Patterns of distant metastases in patients with triple-negative breast cancer\u2014A population\u2010based study. Precis. Med. Sci. 12(3), 182\u201395 (2023).","journal-title":"Precis. Med. Sci."},{"issue":"3","key":"51789_CR68","doi-asserted-by":"publisher","first-page":"164","DOI":"10.5306\/wjco.v12.i3.164","volume":"12","author":"D O\u2019Reilly","year":"2021","unstructured":"O\u2019Reilly, D., Sendi, M. A. & Kelly, C. M. Overview of recent advances in metastatic triple negative breast cancer. World J. Clin. Oncol. 12 (3), 164\u2013182 (2021).","journal-title":"World J. Clin. Oncol."},{"issue":"4","key":"51789_CR69","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.phrs.2008.02.005","volume":"57","author":"J Mojzis","year":"2008","unstructured":"Mojzis, J., Varinska, L., Mojzisova, G., Kostova, I. & Mirossay, L. Antiangiogenic effects of flavonoids and chalcones. Pharmacol. Res. 57 (4), 259\u2013265 (2008).","journal-title":"Pharmacol. Res."},{"key":"51789_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26051356","author":"T Kuruc","year":"2021","unstructured":"Kuruc, T. et al. The newly synthetized chalcone L1 is involved in the cell growth inhibition, induction of apoptosis and suppression of epithelial-to-mesenchymal transition of HeLa cells. Molecules https:\/\/doi.org\/10.3390\/molecules26051356 (2021).","journal-title":"Molecules"},{"issue":"4","key":"51789_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2020.151075","volume":"99","author":"V Cermak","year":"2020","unstructured":"Cermak, V. et al. Microtubule-targeting agents and their impact on cancer treatment. Eur. J. Cell Biol. 99(4), 151075 (2020).","journal-title":"Eur. J. Cell Biol."},{"issue":"1","key":"51789_CR72","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s12885-018-4619-8","volume":"18","author":"AR Harris","year":"2018","unstructured":"Harris, A. R., Perez, M. J. & Munson, J. M. Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression. BMC Cancer. 18 (1), 718 (2018).","journal-title":"BMC Cancer"},{"key":"51789_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210354","author":"R Michalkova","year":"2023","unstructured":"Michalkova, R. et al. Anticancer potential of natural chalcones: In vitro and in vivo evidence. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms241210354 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"51789_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157119","author":"F Postigo-Corrales","year":"2025","unstructured":"Postigo-Corrales, F. et al. Docetaxel resistance in breast cancer: Current insights and future directions. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms26157119 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"51789_CR75","first-page":"2156","volume":"12","author":"M Tufail","year":"2022","unstructured":"Tufail, M., Cui, J. & Wu, C. Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches. Am. j. cancer res. 12, 2156\u20136976 (2022).","journal-title":"Am. j. cancer res."},{"issue":"9","key":"51789_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70803","volume":"14","author":"R Raman","year":"2025","unstructured":"Raman, R., Debata, S., Govindarajan, T. & Kumar, P. Targeting Triple-Negative Breast Cancer: Resistance mechanisms and therapeutic advancements. Cancer Med. 14(9), e70803 (2025).","journal-title":"Cancer Med."},{"issue":"1","key":"51789_CR77","doi-asserted-by":"publisher","first-page":"103","DOI":"10.20517\/cdr.2022.96","volume":"6","author":"AM Scherbakov","year":"2023","unstructured":"Scherbakov, A. M. et al. Targeting hormone-resistant breast cancer cells with docetaxel: A look inside the resistance. Cancer Drug Resist. 6(1), 103\u201315 (2023).","journal-title":"Cancer Drug Resist."},{"key":"51789_CR78","doi-asserted-by":"publisher","DOI":"10.4081\/ejh.2022.3529","volume":"66","author":"J Li","year":"2022","unstructured":"Li, J. et al. Docetaxel-resistant triple-negative breast cancer cell-derived exosomal lncRNA LINC00667 reduces the chemosensitivity of breast cancer cells to docetaxel\u2009<\u2009em>via<\/em> targeting miR-200b-3p\/Bcl-2 axis. Eur. J. Histochem. 66, 3529. https:\/\/doi.org\/10.4081\/ejh.2022.3529 (2022).","journal-title":"Eur. J. Histochem."},{"key":"51789_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101901","volume":"42","author":"A Kar","year":"2024","unstructured":"Kar, A., Agarwal, S., Singh, A., Bajaj, A. & Dasgupta, U. Insights into molecular mechanisms of chemotherapy resistance in cancer. Transl. Oncol. 42, 101901 (2024).","journal-title":"Transl. Oncol."},{"key":"51789_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22010036","author":"M Liu","year":"2016","unstructured":"Liu, M. et al. Xanthohumol, a prenylated chalcone from hops, inhibits the viability and stemness of doxorubicin-resistant MCF-7\/ADR cells. Molecules https:\/\/doi.org\/10.3390\/molecules22010036 (2016).","journal-title":"Molecules"},{"issue":"7","key":"51789_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202400081","volume":"357","author":"J Ram\u00edrez-Prada","year":"2024","unstructured":"Ram\u00edrez-Prada, J. et al. New pyridine-based chalcones and pyrazolines with anticancer, antibacterial, and antiplasmodial activities. Arch. Pharm. (Weinheim) 357(7), 2400081 (2024).","journal-title":"Arch. Pharm. (Weinheim)"},{"issue":"1","key":"51789_CR82","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12935-023-03009-2","volume":"23","author":"Z Gholizadeh Siahmazgi","year":"2023","unstructured":"Gholizadeh Siahmazgi, Z., Irani, S., Ghiaseddin, A., Fallah, P. & Haghpanah, V. Xanthohumol hinders invasion and cell cycle progression in cancer cells through targeting MMP2, MMP9, FAK and P53 genes in three-dimensional breast and lung cancer cells culture. Cancer Cell Int. 23(1), 153 (2023).","journal-title":"Cancer Cell Int."},{"key":"51789_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094478","author":"V Harish","year":"2021","unstructured":"Harish, V. et al. Xanthohumol for human malignancies: Chemistry, pharmacokinetics and molecular targets. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22094478 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"51789_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110487","volume":"101","author":"A Acosta-Casique","year":"2023","unstructured":"Acosta-Casique, A. et al. ERK activation modulates invasiveness and reactive oxygen species (ROS) production in triple negative breast cancer cell lines. Cell Signal. 101, 110487 (2023).","journal-title":"Cell Signal."},{"issue":"1","key":"51789_CR85","doi-asserted-by":"publisher","first-page":"101642","DOI":"10.1016\/j.gendis.2025.101642","volume":"13","author":"H Xie","year":"2026","unstructured":"Xie, H. et al. OTX1 promotes TNBC cell proliferation and tumor growth through the ERK pathway. Genes Dis. 13 (1), 101642 (2026).","journal-title":"Genes Dis."},{"key":"51789_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9050052","author":"P Wee","year":"2017","unstructured":"Wee, P. & Wang, Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers9050052 (2017).","journal-title":"Cancers (Basel)"},{"key":"51789_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112748","author":"ML Uribe","year":"2021","unstructured":"Uribe, M. L., Marrocco, I. & Yarden, Y. EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13112748 (2021).","journal-title":"Cancers (Basel)"},{"issue":"2","key":"51789_CR88","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ceb.2007.02.010","volume":"19","author":"SR Hubbard","year":"2007","unstructured":"Hubbard, S. R. & Miller, W. T. Receptor tyrosine kinases: Mechanisms of activation and signaling. Curr. Opin. Cell Biol. 19(2), 117\u201323 (2007).","journal-title":"Curr. Opin. Cell Biol."},{"issue":"5","key":"51789_CR89","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.tcb.2015.12.006","volume":"26","author":"X Tan","year":"2016","unstructured":"Tan, X., Lambert, P. F., Rapraeger, A. C. & Anderson, R. A. Stress-induced EGFR trafficking: Mechanisms, functions, and therapeutic implications. Trends Cell Biol. 26(5), 352\u201366 (2016).","journal-title":"Trends Cell Biol."},{"issue":"22","key":"51789_CR90","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1038\/sj.onc.1210414","volume":"26","author":"S Meloche","year":"2007","unstructured":"Meloche, S. & Pouyssegur, J. The ERK1\/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26 (22), 3227\u20133239 (2007).","journal-title":"Oncogene"},{"issue":"1","key":"51789_CR91","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43046-024-00233-3","volume":"36","author":"S Moulik","year":"2024","unstructured":"Moulik, S., Karmakar, S., Basu, A., Ali, M. & Chatterjee, A. Interdependency and differential expression of ERK1 and ERK2 in breast and melanoma cell lines. J. Egypt. Natl. Canc. Inst. 36(1), 27 (2024).","journal-title":"J. Egypt. Natl. Canc. Inst."},{"issue":"10","key":"51789_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2022.119317","volume":"1869","author":"P Wolf","year":"2022","unstructured":"Wolf, P., Schoeniger, A. & Edlich, F. Pro-apoptotic complexes of BAX and BAK on the outer mitochondrial membrane. Biochimica et Biophysica Acta (BBA) 1869(10), 119317 (2022).","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"7","key":"51789_CR93","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nm1263","volume":"11","author":"G Kroemer","year":"2005","unstructured":"Kroemer, G. & Martin, S. J. Caspase-independent cell death. Nat. Med. 11(7), 725\u201330 (2005).","journal-title":"Nat. Med."},{"issue":"1","key":"51789_CR94","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/1673-5374.286946","volume":"16","author":"HA Park","year":"2021","unstructured":"Park, H. A., Broman, K. & Jonas, E. A. Oxidative stress battles neuronal Bcl-xL in a fight to the death. Neural Regen. Res. 16(1), 12\u20135 (2021).","journal-title":"Neural Regen. Res."},{"issue":"7","key":"51789_CR95","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.bpj.2020.08.014","volume":"119","author":"P Ryzhov","year":"2020","unstructured":"Ryzhov, P. et al. Conformational states of the cytoprotective protein Bcl-xL. Biophys. J. 119(7), 1324\u201334 (2020).","journal-title":"Biophys. J."},{"issue":"1","key":"51789_CR96","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41419-025-07873-w","volume":"16","author":"P Fischer","year":"2025","unstructured":"Fischer, P. et al. Molecular features of TNBC govern heterogeneity in the response to radiation and autophagy inhibition. Cell Death Dis. 16(1), 540 (2025).","journal-title":"Cell Death Dis."},{"key":"51789_CR97","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2021.06.013","volume":"172","author":"T Shi","year":"2021","unstructured":"Shi, T., van Soest, D. M. K., Polderman, P. E., Burgering, B. M. T. & Dansen, T. B. DNA damage and oxidant stress activate p53 through differential upstream signaling pathways. Free Radic. Biol. Med. 172, 298\u2013311 (2021).","journal-title":"Free Radic. Biol. Med."},{"issue":"4","key":"51789_CR98","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","volume":"20","author":"A Hafner","year":"2019","unstructured":"Hafner, A., Bulyk, M. L., Jambhekar, A. & Lahav, G. The multiple mechanisms that regulate p53 activity and cell fate. Nat. Rev. Mol. Cell Biol. 20 (4), 199\u2013210 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"51789_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11071037","author":"V Atsaves","year":"2019","unstructured":"Atsaves, V., Leventaki, V., Rassidakis, G. Z. & Claret, F. X. AP-1 transcription factors as regulators of immune responses in cancer. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers11071037 (2019).","journal-title":"Cancers (Basel)"},{"issue":"1","key":"51789_CR100","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-020-01686-9","volume":"39","author":"A Brennan","year":"2020","unstructured":"Brennan, A., Leech, J. T., Kad, N. M. & Mason, J. M. Selective antagonism of cJun for cancer therapy. J. Exp. Clin. Cancer Res. 39 (1), 184 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"29","key":"51789_CR101","doi-asserted-by":"publisher","first-page":"31776","DOI":"10.1021\/acsomega.5c02807","volume":"10","author":"S Sensenbach","year":"2025","unstructured":"Sensenbach, S. et al. The role of c\u2013Jun signaling in cytidine analog-induced cell death in melanoma. ACS. Omega 10(29), 31776\u201331788 (2025).","journal-title":"ACS. Omega"},{"issue":"18","key":"51789_CR102","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1038\/onc.2016.417","volume":"36","author":"X Xie","year":"2017","unstructured":"Xie, X. et al. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun. Oncogene 36 (18), 2599\u20132608 (2017).","journal-title":"Oncogene"},{"issue":"45","key":"51789_CR103","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1038\/sj.onc.1203173","volume":"18","author":"S Lepp\u00e4","year":"1999","unstructured":"Lepp\u00e4, S. & Bohmann, D. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 18 (45), 6158\u20136162 (1999).","journal-title":"Oncogene"},{"issue":"5","key":"51789_CR104","doi-asserted-by":"publisher","first-page":"E131","DOI":"10.1038\/ncb0502-e131","volume":"4","author":"E Shaulian","year":"2002","unstructured":"Shaulian, E. & Karin, M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4 (5), E131\u2013E6 (2002).","journal-title":"Nat. Cell Biol."},{"issue":"2","key":"51789_CR105","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ceb.2007.02.001","volume":"19","author":"CR Weston","year":"2007","unstructured":"Weston, C. R. & Davis, R. J. The JNK signal transduction pathway. Curr. Opin. Cell Biol. 19(2), 142\u20139 (2007).","journal-title":"Curr. Opin. Cell Biol."},{"key":"51789_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.871667","volume":"9","author":"A Fouzat","year":"2022","unstructured":"Fouzat, A. et al. Elaeagnus angustifolia plant extract induces apoptosis via P53 and Signal Transducer and Activator of Transcription 3 signaling pathways in triple-negative breast cancer cells. Front. Nutr. 9, 871667 (2022).","journal-title":"Front. Nutr."},{"issue":"5","key":"51789_CR107","doi-asserted-by":"publisher","first-page":"e27002","DOI":"10.1016\/j.heliyon.2024.e27002","volume":"10","author":"AF Hassan","year":"2024","unstructured":"Hassan, A. F. et al. The effect of novel nitrogen-based chalcone analogs on colorectal cancer cells: Insight into the molecular pathways. Heliyon 10 (5), e27002 (2024).","journal-title":"Heliyon"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51789-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51789-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51789-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:01:58Z","timestamp":1791277318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51789-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51789"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51789-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: The Acknowledgements section was missing. The correct information now accompanies the original Article.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: We filed a USA patent application number 18\/907, 427 on Oct 04, 2024. It is still under review.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24800"}}